Evidence map›Paper›PMID 25761747›Full record

ArticleJournal of molecular neuroscience : MN2015

CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.

Terry W Moody, Bernardo Nuche-Berenguer, Paola Moreno, Robert T Jensen

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular neuroscience : MN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Construction and analysis of the ceRNA networkAnnals of translational medicine · 2021
    Article
  5. Article
  6. Review
  7. Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases.American journal of physiology. Gastrointestinal and liver physiology · 2019
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Terry W MoodyDepartment of Health and Human Services, National Cancer Institute, Center for Cancer Research, Office of the Director, 9609 Medical Center Drive, Room 2 W-130, Bethesda, MD, 20892, USA, moodyt@mail.nih.gov.
Bernardo Nuche-Berenguer
Paola Moreno
Robert T Jensen
National Institutes of Health · USNational Cancer Institute · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Cellular Basis Of Action Of Gastrointestinal Peptides/Growth factorsZIADK053101 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JENSEN, ROBERT · 2009 to 2025
$12.9M
Characterization And Pharmacology Of Receptors For Gastrointestinal PeptidesZIADK053100 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JENSEN, ROBERT · 2009 to 2025
$12.7M
Intramural NIH HHS Z99 DK999999Intramural NIH HHS ZIA DK053100Intramural NIH HHS ZIA DK053101
6 · The paper itself

Abstract

Cholecystokinin (CCK) receptors are G-protein coupled receptors (GPCR) which are present on lung cancer cells. CCK-8 stimulates the proliferation of lung cancer cells, whereas the CCK2R receptor antagonist CI-988 inhibits proliferation. GPCR for some gastrointestinal hormones/neurotransmitters mediate lung cancer growth by causing epidermal growth factor receptor (EGFR) transactivation. Here, the role of CCK/gastrin and CI-988 on EGFR transactivation and lung cancer proliferation was investigated. Addition of CCK-8 or gastrin-17 (100 nM) to NCI-H727 human lung cancer cells increased EGFR Tyr(1068) phosphorylation after 2 min. The ability of CCK-8 to cause EGFR tyrosine phosphorylation was blocked by CI-988, gefitinib (EGFR tyrosine kinase inhibitor), PP2 (Src inhibitor), GM6001 (matrix metalloprotease inhibitor), and tiron (superoxide scavenger). CCK-8 nonsulfated and gastrin-17 caused EGFR transactivation and bound with high affinity to NCI-H727 cells, suggesting that the CCK2R is present. CI-988 inhibited the ability of CCK-8 to cause ERK phosphorylation and elevate cytosolic Ca(2+). CI-988 or gefitinib inhibited the basal growth of NCI-H727 cells or that stimulated by CCK-8. The results indicate that CCK/gastrin may increase lung cancer proliferation in an EGFR-dependent manner.

Indexed as

1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium SaltAntineoplastic AgentsCell Line, TumorCell ProliferationDipeptidesErbB ReceptorsGastrinsGefitinibHormone AntagonistsHumansIndolesLung NeoplasmsMegluminePyrimidinesQuinazolines1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium SaltAG 1879Antineoplastic AgentsDipeptidesErbB Receptorsgastrin 17GastrinsGefitinibHormone AntagonistsIndolesMeglumineN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamidePD 134308PyrimidinesQuinazolines

Identifiers

PMID25761747
PMCPMC4479967
OpenAlexW2089690531

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.